Skip to main content

Table 1 Cohort demographics

From: Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

Cohort 1

    
 

NC

(n = 8)

PMC

(n = 16)

PPA

(n = 13)

bvFTD

(n = 16)

Age, median years (range)a

52 (24–65)

53 (31–71)

65 (52–79)

61 (40–78)

Female, N (%)

4 (50)

10 (62)

8 (57)

6 (37)

Age at onset, median years (range)

63 (50–78)

59 (39–77)

Years to expected onsetb, median years (range)

8 (−24,+ 3)

Mutation, N (%)

C9orf72

8 (50)

0

2 (13)

GRN

8 (50)

1 (8)

VCP

1 (6)

Cohort 2

Control

(n = 18)

FTDc

(n = 13)

AD

(n = 79)

 

Age, median years (range)d

81 (74–86)

68 (50–83)

72 (54–88)

 

Female, N (%)

10 (56)

4 (31)

49 (62)

 
  1. NC Non carriers, PMC Presymptomatic mutation carriers, PPA Primary progressive aphasia, bvFTD – behavioural variant FTD, AD Alzheimer’s disease
  2. a Differences in age were found between PPA and unaffected individuals (ANOVA, p = 0.001, pairwise post hoc test PPA vs NC, p = 0.01, PPA vs PMC, p = 0.01). Differences where found between FTD as a whole group and unaffected individuals (t-test, p < 0.001)
  3. b Difference between the subjects age at sampling and the mean age at onset in their family
  4. c Clinical phenotype: 7 bvFTD and 5 SD
  5. d Differences in age were found between controls and FTD/AD (ANOVA, p < 0.001, pairwise post hoc test controls vs FTD, p < 0.001, controls vs AD, p < 0.001)